logo

For the Inventor, By the Inventor

Le Manoir, France

Sophie Philippe Coupa

This inventor holds 11 USPTO granted patents. Top assignee: Janssen Pharmaceutica Nv. Active years: 2006-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sophie Philippe Coupa. Retrieved from https://idiyas.com/inventor/sophie-philippe-coupa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 45.5

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 31(Granted Patents)


Location History:

  • Le Manoir sure Seine, FR (2009)
  • Louviers, FR (2009 - 2012)
  • Issy-les-Moulineaux, FR (2006 - 2021)
  • Belbeuf, FR (2013 - 2023)

Company Filing History:

goldMedal11 out of 2,101 
 
Janssen Pharmaceutica Nv
 patents

Years Active: 2006-2023

Loading Chart...
11 patents (USPTO):Explore Patents
1. 11583524 - Inhibitors of the interaction between MDM2 and P53 (2023-02-21),
2. 10894793 - Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors (2021-01-19),
3. 10202387 - Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors (2019-02-12),
4. 10087187 - Imidazopyridazine derivatives as PI3KB inhibitors (2018-10-02),
5. 9573933 - Inhibitors of the interaction between MDM2 and P53 (2017-02-21),
6. 8604200 - [object Object] (2013-12-10),
7. 8138334 - Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists (2012-03-20),
8. 7629468 - Metabotropic glutamate receptor antagonists (2009-12-08),
9. 7612056 - Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists (2009-11-03),
10. 7544694 - Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists (2009-06-09),
11. 7115630 - Metabotropic glutamate receptor antagonists (2006-10-03),

Title: Innovations by Sophie Philippe Coupa: A Pioneering Inventor

Introduction

Sophie Philippe Coupa is a remarkable inventor based in Le Manoir, France. With a total of 11 patents, she has made significant contributions to the field of pharmaceutical chemistry, focusing on innovative compounds for medical applications. Her latest inventions showcase her expertise and dedication to advancing healthcare solutions.

Latest Patents

Sophie Coupa's recent patents reflect her pioneering spirit in the development of pharmaceuticals. One of her notable inventions is an inhibitor of the interaction between MDM2 and P53. This invention provides compounds of a specific formula that serve as inhibitors of the p53-MDM2 interaction, offering potential therapeutic applications for various diseases.

Additionally, she has developed bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors. This invention includes compounds that are defined by a unique formula, showcasing their utility as potent PI3Kβ inhibitors. The compounds are also integrated into pharmaceutical compositions, demonstrating her commitment to creating effective medications.

Career Highlights

Currently, Sophie Philippe Coupa is affiliated with Janssen Pharmaceutica NV, a leading pharmaceutical company that values innovation and research. Her work at this esteemed institution allows her to contribute to significant advancements in medicine.

Collaborations

Throughout her career, Sophie has collaborated with notable colleagues, including Alain Philippe Poncelet and Bruno Schoentjes. These partnerships have fostered an environment of creativity and innovation, culminating in a wealth of intellectual property that benefits the medical community.

Conclusion

Sophie Philippe Coupa exemplifies the spirit of innovation in the pharmaceutical industry. With her impressive track record of 11 patents, her contributions continue to pave the way for new therapeutic solutions. As she pushes the boundaries of scientific discovery, her work not only enhances our understanding of complex medical interactions but also provides hope for effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…